Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.79 |
| ▸ | MAOA | P21397 | 1/20 | 0.79 |
| ▸ | HTR2B | P41595 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.69 |
| ▸ | CASR | P41180 | 5/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11747215 | 0.90 | HTR1A (0.79) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL5460114 | 0.89 | HTR1A (0.77) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL5460117 | 0.89 | HTR1A (0.77) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| SCHEMBL5460120 | 0.89 | HTR1A (0.77) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| Bunitrolol SCHEMBL29354749 | 0.88 | HTR1A (1.00) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| Bunitrolol SCHEMBL34720 | 0.88 | HTR1A (1.00) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| Bunitrolol SCHEMBL34721 | 0.88 | HTR1A (1.00) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| Bunitrolol SCHEMBL6506350 | 0.88 | HTR1A (1.00) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| Bunitrolol SCHEMBL142695 | 0.87 | HTR1A (0.97) | HTR1AADRA2AADRA2BMAOAHTR2B | |
| Bunitrolol SCHEMBL6061096 | 0.87 | HTR1A (0.97) | HTR1AADRA2AADRA2BMAOAHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | claimed |
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2017-01-05 | — | — | US | claimed |
| US-9498481-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | claimed |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2016-07-07 | — | — | US | claimed |
| US-9255104-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2014-09-25 | — | — | US | claimed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-8575348-B2 | Quinolone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC (US) | 2013-11-05 | — | — | US | claimed |
| US-20120301458-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| US-20110136861-A1 | QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | claimed |
| WO-2011017108-A2 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0229947-B1 | NOVEL CRYSTALLINE SALTS OF ARYLOXY-PROPANOLAMINES, THEIR PREPARATION AND THEIR USE | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-03-13 | — | — | EP | claimed |
| US-4849530-A | Process for the preparation of crystalline salts or aryloxy-propanolamines | RORER PHARMACEUTICAL CORPORATION (US) | 1989-07-18 | — | — | US | claimed |
| US-4767784-A | DIPHENYLACETATES | RORER PHARMACEUTICAL CORPORATION | 1988-08-30 | — | — | US | claimed |
| EP-0229947-A1 | Novel crystalline salts of aryloxy-propanolamines, their preparation and their use | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-07-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | HTR1A 283/4885ADRA2A 111/4885ADRA2B 130/4885 |
| US-20110136861-A1 | QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G12A, PLA2G4A, PLA2G2A | HTR1A 1455/4885ADRA2A 359/4885ADRA2B 426/4885 |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | HTR1A 283/4885ADRA2A 111/4885ADRA2B 130/4885 |
| US-20120301458-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | HTR1A 318/4885ADRA2A 91/4885ADRA2B 110/4885 |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | HTR1A 1445/4885ADRA2A 769/4885ADRA2B 919/4885 |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | HTR1A 283/4885ADRA2A 111/4885ADRA2B 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.